8-KMaterial AgreementsFinancial EventsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Material Agreement (Jul 26, 2013)

Filed July 26, 2013For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) announced on July 25, 2013, the execution of a new $1.5 billion, 5-year senior unsecured revolving credit facility. This new facility replaces the company's previous $1 billion revolving credit agreement, indicating an increase in available credit. The proceeds from the new credit facility are earmarked for various corporate uses, including repaying the prior agreement, working capital, capital expenditures, acquisitions, stock repurchases, debt refinancing, and other general corporate purposes. This update provides investors with insight into the company's strengthened liquidity position and its strategic flexibility. The increased credit line, coupled with the defined uses for the funds, suggests Thermo Fisher Scientific is well-positioned for potential growth opportunities, operational needs, or strategic M&A activities. The new agreement also includes specific financial covenants, particularly concerning the debt-to-EBITDA ratio and an interest coverage ratio, which will be adjusted following the consummation of the Life Technologies Corporation acquisition, signaling a focus on maintaining financial discipline through growth phases.

Key Highlights

  • 1Thermo Fisher Scientific entered into a new $1.5 billion, 5-year senior unsecured revolving credit agreement.
  • 2The new credit facility replaces the company's prior $1 billion revolving credit agreement, increasing available credit by $500 million.
  • 3Proceeds can be used for working capital, capital expenditures, acquisitions, stock repurchases, debt refinancing, and general corporate purposes.
  • 4Interest rates are variable and depend on the company's Debt Ratings, ranging from 0.900% to 1.700% for Eurocurrency Rate Loans and 0.000% to 0.700% for Base Rate Loans.
  • 5A facility fee of 0.100% to 0.300% per year on aggregate commitments is payable based on Debt Ratings.
  • 6The agreement includes negative covenants restricting liens, subsidiary debt, fundamental changes, dispositions, and affiliate transactions.
  • 7Key financial covenants include a maximum consolidated indebtedness to consolidated EBITDA ratio, which adjusts post-acquisition of Life Technologies Corporation, and a minimum interest coverage ratio requirement.

Frequently Asked Questions

The primary purpose of the new $1.5 billion credit agreement is to provide Thermo Fisher Scientific with enhanced financial flexibility. The funds can be used for a variety of strategic and operational needs, including repaying existing debt, funding working capital, capital expenditures, acquisitions, stock repurchases, and general corporate purposes.

The new credit facility is a $1.5 billion, 5-year senior unsecured revolving credit agreement, replacing the company's previous $1 billion, 5-year revolving credit agreement. This represents a $500 million increase in the company's available revolving credit line.

The agreement includes covenants such as a maximum consolidated indebtedness to consolidated EBITDA ratio and a minimum interest coverage ratio of 3.0 to 1.0 (required after the Life Technologies acquisition). The debt-to-EBITDA covenant has a tiered structure that adjusts based on the timeframe following the Life Technologies acquisition, starting at 3.5:1.0 and increasing temporarily before returning to 3.5:1.0 by maturity.

The increased credit line suggests Thermo Fisher Scientific is securing robust financing to support its growth initiatives, which may include significant capital expenditures or strategic acquisitions, such as the then-pending acquisition of Life Technologies Corporation. It demonstrates a proactive approach to maintaining liquidity and the capacity to pursue value-enhancing opportunities while adhering to financial covenants.